Premium
Cancer‐stromal cell fusion as revealed by fluorescence protein tracking
Author(s) -
Wang Ruoxiang,
Lewis Michael S.,
Lyu Ji,
Zhau Haiyen E.,
Pandol Stephen J.,
Chung Leland W. K.
Publication year - 2020
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/pros.23941
Subject(s) - stromal cell , cell fusion , lncap , cancer research , biology , cancer cell , fusion protein , fusion gene , cancer , cell , prostate cancer , cell culture , genetics , gene , recombinant dna
Purpose We previously determined that cancer‐stromal interaction was a direct route to tumor cell heterogeneity progression, since cancer‐stromal cell fusion in coculture resulted in the creation of heterogeneous clones of fusion hybrid progeny. In this report, we modified the cancer‐stromal coculture system to establish optimal experimental conditions for investigating cell fusion machinery and the mechanism of heterogeneity progression. Experimental design Red fluorescence protein‐tagged LNCaP cells were cocultured with green fluorescence protein‐labeled prostate stromal cells for cancer‐stromal cell fusion, which was tracked as dual fluorescent cells by fluorescence microscopy. Results We identified the most efficient strategy to isolate clones of fusion hybrid progenies. From the coculture, mixed cells including fusion hybrids were subjected to low‐density replating for colony formation by fusion hybrid progeny. These colonies could propagate into derivative cell populations. Compared to the parental LNCaP cells, clones of the fusion hybrid progeny displayed divergent behaviors and exhibited permanent genomic hybridization. Conclusions Cancer‐stromal cell fusion leads to cancer cell heterogeneity. The cancer‐stromal coculture system characterized in this study can be used as a model for molecular characterization of cancer cell fusion as the mechanism behind the progression of heterogeneity observed in clinical prostate cancers.